Tarek Y. El Ahmadieh

Tarek Y. El Ahmadieh

Auto-generated profile, based on publicly available information

Tarek Y. El Ahmadieh

Department of Neurological Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in Journal of Neurosurgery
Verified
Journal Article
Open access
PDF file
EWEva M. Wu
Eva M. Wu
TATarek Y. El Ahmadieh
Tarek Y. El Ahmadieh
CMCameron M. McDougall
Cameron M. McDougall
SASalah G. Aoun
Salah G. Aoun
NMNikhil Mehta
Nikhil Mehta
BWBabu G. Welch
Babu G. Welch
OBJECTIVE: Endovascular embolization has been established as an adjuvant treatment strategy for brain arteriovenous malformations (AVMs). A growing body of literature has discussed curative embolization for select lesions. The transition of endovascular embolization from an adjunctive to a definitive treatment modality remains controversial. Here, the authors reviewed the literature to assess the lesional characteristics, technical factors, and angiographic and clinical outcomes of endovascular embolization of AVMs with intent to cure.METHODS: Electronic databases—Ovid MEDLINE, Ovid Embase, and PubMed—were searched for studies in which there was evidence of AVMs treated using endovascular embolization with intent to cure. The primary outcomes of interest were angiographic obliteration immediately postembolization and at follow-up. The secondary outcomes of interest were complication rates. Descriptive statistics were used to calculate rates and means.RESULTS: Fifteen studies with 597 patients and 598 AVMs treated with intent-to-cure embolization were included in this analysis. Thirty-four percent of AVMs were Spetzler-Martin grade III. Complete obliteration immediately postembolization was reported in 58.3% of AVMs that had complete treatment and in 45.8% of AVMs in the entire patient cohort. The overall clinical complication rate was 24.1%. The most common complication was hemorrhage, occurring in 9.7% of patients. Procedure-related mortality was 1.5%.CONCLUSIONS: While endovascular embolization with intent to cure can be an option for select AVMs, the reported complication rates appear to be increased compared with those in studies in which adjunctive embolization was the goal. Given the high complication rate related to a primary embolization approach, the risks and benefits of such a treatment strategy should be discussed among a multidisciplinary team. Curative embolization of AVMs should be considered an unanticipated benefit of such therapy rather than a goal.

23 March 2021 in Cells
Verified
Journal Article
Open access
PDF file
William HicksWilliam Hicks
William Hicks
CBCylaina Bird
Cylaina Bird
Jeffrey TraylorJeffrey Traylor
Jeffrey Traylor
DSDiana Shi
Diana Shi
TATarek Y. El Ahmadieh
Tarek Y. El Ahmadieh
KAKalil Abdullah
Kalil Abdullah
Despite advances in understanding of the molecular pathogenesis of glioma, outcomes remain dismal. Developing successful treatments for glioma requires faithful in vivo disease modeling and rigorous preclinical testing. Murine models, including xenograft, syngeneic, and genetically engineered models, are used to study glioma-genesis, identify methods of tumor progression, and test novel treatment strategies. Since the discovery of highly recurrent isocitrate dehydrogenase (IDH) mutations in lower-grade gliomas, there is increasing emphasis on effective modeling of IDH mutant brain tumors. Improvements in preclinical models that capture the phenotypic and molecular heterogeneity of gliomas are critical for the development of effective new therapies. Herein, we explore the current status, advancements, and challenges with contemporary murine glioma models.

26 November 2021 in Cancers
Verified
Journal Article
Open access
PDF file
PPPaolo Palmisciano
Paolo Palmisciano
AHAli S. Haider
Ali S. Haider
MSMohammadmahdi Sabahi
Mohammadmahdi Sabahi
CNChibueze D. Nwagwu
Chibueze D. Nwagwu
OBOthman Bin-Alamer
Othman Bin-Alamer
OPOmar Pathmanaban
Omar Pathmanaban
Background: Primary skull base chondrosarcomas (SBCs) can severely affect patients’ quality of life. Surgical-resection and radiotherapy are feasible but may cause debilitating complications. We systematically reviewed the literature on primary SBCs. Methods: PubMed, EMBASE, Scopus, Web-of-Science, and Cochrane were searched following the PRISMA guidelines to include studies of patients with primary SBCs. Clinical characteristics, management strategies, and treatment outcomes were analyzed. Results: We included 33 studies comprising 1307 patients. Primary SBCs mostly involved the middle-fossa (72.7%), infiltrating the cavernous-sinus in 42.4% of patients. Cranial-neuropathies were reported in 810 patients (62%). Surgical-resection (93.3%) was preferred over biopsy (6.6%). The most frequent open surgical approaches were frontotemporal-orbitozygomatic (17.6%) and pterional (11.9%), and 111 patients (21.3%) underwent endoscopic-endonasal resection. Post-surgical cerebrospinal-fluid leaks occurred in 36 patients (6.5%). Radiotherapy was delivered in 1018 patients (77.9%): photon-based (41.4%), proton-based (64.2%), and carbon-based (13.1%). Severe post-radiotherapy complications, mostly hypopituitarism (15.4%) and hearing loss (7.1%) were experienced by 251 patients (30.7%). Post-treatment symptom-improvement (46.7%) and reduced/stable tumor volumes (85.4%) showed no differences based on radiotherapy-protocols (p = 0.165; p = 0.062). Median follow-up was 67-months (range, 0.1–376). SBCs recurrences were reported in 211 cases (16.1%). The 5-year and 10-year progression-free survival rates were 84.3% and 67.4%, and overall survival rates were 94% and 84%. Conclusion: Surgical-resection and radiotherapy are effective treatments in primary SBCs, with acceptable complication rates and favorable local tumor control.

3 November 2021 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
WHWilliam H. Hicks
William H. Hicks
CBCylaina E. Bird
Cylaina E. Bird
MPMark N. Pernik
Mark N. Pernik
AHAli S. Haider
Ali S. Haider
ADAksharkumar Dobariya
Aksharkumar Dobariya
TATarek Y. EL Ahmadieh
Tarek Y. EL Ahmadieh
Enhanced understanding of the molecular features of glioma has led to an expansion of murine glioma models and successful preclinical studies. However, clinical trials continue to have a high cost, extended production time, and low proportion of success. Studies in large-animal models of various cancer types have emerged to bridge the translational gap between in vitro and in vivo animal studies and human clinical trials. The anatomy and physiology of large animals are of more direct relevance to human disease, allowing for more rigorous testing of treatments such as surgical resection and adjuvant therapy in glioma. The recent generation of multiple porcine glioma models supports their use in high-throughput preclinical studies. The demonstration of spontaneous glioblastoma formation in canines further provides a unique avenue for the study of de novo glioma. The aim of this review was to outline the current status of large animal models of glioma and their value as a transitional step between rodent models and human clinical trials.

3 July 2021 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PPPaolo Palmisciano
Paolo Palmisciano
AHAli S. Haider
Ali S. Haider
CNChibueze D. Nwagwu
Chibueze D. Nwagwu
WWWaseem Wahood
Waseem Wahood
SASalah G. Aoun
Salah G. Aoun
TATarek Y. El Ahmadieh
Tarek Y. El Ahmadieh

19 November 2021 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
PPPaolo Palmisciano
Paolo Palmisciano
TATarek Y. El Ahmadieh
Tarek Y. El Ahmadieh
AHAli S. Haider
Ali S. Haider
OAOthman Bin Alamer
Othman Bin Alamer
FRFaith C. Robertson
Faith C. Robertson
RSRaymond Sawaya
Raymond Sawaya